Invention Grant
US09120842B2 SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
有权
SPARC衍生的肿瘤排斥抗原肽和包含其的药物
- Patent Title: SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
- Patent Title (中): SPARC衍生的肿瘤排斥抗原肽和包含其的药物
-
Application No.: US13901194Application Date: 2013-05-23
-
Publication No.: US09120842B2Publication Date: 2015-09-01
- Inventor: Yasuharu Nishimura , Yoshiaki Ikuta , Shuichi Nakatsuru
- Applicant: ONCO THERAPY SCIENCE, INC.
- Applicant Address: JP Kanagawa
- Assignee: ONCO THERAPY SCIENCE, INC.
- Current Assignee: ONCO THERAPY SCIENCE, INC.
- Current Assignee Address: JP Kanagawa
- Agency: Greenblum & Bernstein, P.L.C.
- Priority: JP2006-167724 20060616
- Main IPC: C07K7/06
- IPC: C07K7/06 ; A61K39/00 ; C07K14/47 ; C07K16/18 ; A61K38/00
Abstract:
It is an objective of the present invention to identify SPARC protein-derived peptides that are able to induce human killer T cells and helper T cells having cytotoxic activity to tumors, and to provide a means for carrying out a tumor immunotherapy of patients with various types of cancers overexpressing SPARC. The present invention provides a peptide of any of the following: (A) a peptide which consists of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide which consists of an amino acid sequence comprising a substitution or addition of one or several amino acids with respect to the peptide consisting of the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has capacity to induce cytotoxic (killer) T cells.
Public/Granted literature
- US20130288363A1 SPARC-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES AND MEDICAMENTS COMPRISING THE SAME Public/Granted day:2013-10-31
Information query
